Latest Headlines

Latest Headlines

Immunocore and Lilly strike a risk-sharing deal in oncology R&D

Immunocore has struck another cancer R&D pact with one of the world's top drugmakers, signing a deal with Eli Lilly that'll both bring in short-term revenue and help the biotech build value in its proprietary pipeline.

Merck KGaA brings in a new R&D boss amid its global rethink

Merck KGaA, in the middle of a reformation plot in its biopharma division, has found a new head of drug R&D, moving on after its last research chief lasted just 6 months in the job.

President's advisory group calls for clinical trial changes, incentives for antibiotics R&D

With antibiotic resistance on the rise at a time when Big Pharma has largely left the risk-heavy field, the President's Council of Advisors on Science and Technology is proposing a number of recommendations to lure companies back into the arena and help speed up the development of new antibiotics.

Massachusetts med tech outfit wins $1M from NIH to develop pediatric stent system

480 Biomedical won $1 million in Phase II funding from the National Heart, Lung, and Blood Institute (NHLBI) to support development of its self-expanding scaffold for patients with pediatric artery stenosis (PAS).

Virtual Finger provides faster, better way to study 3D images

The tool will allow users to sift through three-dimensional images, such as synapses or neurons, more efficiently and comprehensively than previous technology allowed.

PEDv diagnostic hits market as vets predict 2.5 million more deaths

With the porcine epidemic diarrhea virus wiping out some 100,000 piglets a week, animal health company VMRD has developed a diagnostic tool that can be used to detect antibody to the virus.

China's HD Bio teams with Marshall U. for cancer R&D

Chinese clinical research outfit HD Biosciences has struck a deal with Marshall University to collaborate on cancer drug development, sharing costs and risks in hopes of commercializing new therapies.

When will Big Pharma get serious about antibiotic R&D?

The 5 most promising antibiotic treatments in the industry's pipeline all have something in common: Not one was developed by Big Pharma.

Ebola outbreak rages on as drug development remains slow

As the death toll from West Africa's Ebola outbreak hits nearly 540--a 60% mortality rate--drug development for the untreatable disease is lagging, largely due to lack of interest from Big Pharma and the relative infrequency of the disease.

DOD awards $40M for wireless implant for memory loss due to brain injury

Soon, there will be a device to cure some forgetfulness if the Department of Defense's four-year grant of up to $40 million succeeds in fostering implants and electronic interfaces that diagnose and treat memory loss due to traumatic brain injury.